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Our recent microarray study reported altered mRNA expression of several low density 
lipoprotein receptor-related proteins (LRP) associated with the first 4 years following diagnosis 
with schizophrenia. Whilst this finding is novel, apolipoprotein E (APOE), which mediates its 
activity through LRPs, has been reported by several studies to be altered in brains of subjects 
with schizophrenia. We used qPCR to measure the expression of LRP2, LRP4, LRP6, LRP8, 
LRP10 and LRP12 mRNA in Brodmann’s area (BA) 46 of the dorsolateral prefrontal cortex in 15 
subjects with short duration of illness schizophrenia (SDS) and 15 pair matched controls. We 
also used Western blotting to measure APOE protein expression in BA46 from these subjects. 
Amongst the LRPs examined, LRP10 expression was significantly increased (P = 0.03) and LRP12 
was significantly decreased (P < 0.01) in SDS. APOE protein expression was also increased in 
SDS (P = 0.01). No other marker examined in this study was altered with diagnosis. Our data 
supports a role for distinct members of the LRP family in the pathology of schizophrenia and 
adds weight to the hypothesis that aberrant apolipoprotein signaling is involved in the early 
stages of schizophrenia.
Keywords: schizophrenia, low density lipoprotein receptor-related proteins, apolipoprotein E, prefrontal cortex, 
Brodmann’s area 46
Edited by:
Ming D. Li, University of Virginia, USA
Reviewed by:
Xiangning Chen, Virginia 
Commonwealth University, USA
Ju Wang, University of Virginia, USA
*Correspondence:
Andrew Stuart Gibbons, The Rebecca 
L. Cooper Research Laboratories, The 
Mental Health Research Institute of 
Victoria, 155 Oak Street, Parkville, VIC 
3052, Australia.
e-mail: a.gibbons@mhri.edu.au
Our previous microarray study suggests altered mRNA expres-
sion of several LRPs in Brodmann’s Area (BA) 46 is associated 
with SDS (Narayan et al., 2008) but not LDS, suggesting altered 
LRP expression may be specifically involved in processes associated 
with the early progression of schizophrenia. Thus, we used qPCR to 
further interrogate the expression of several members of the LRP 
family that were identified as potentially altered in the initial screen 
of our microarray data, in BA 46 from subjects with SDS. We also 
examined the protein expression levels of ApoE in these subjects 
to see whether changes in LRP expression could be reflective of 
abnormal lipoprotein signaling.
Materials and Methods
tissue ColleCtion
All tissue was obtained from the Victorian Brain Bank Network at the 
Mental Health Research Institute of Victoria; the study was performed 
following the approval of the Ethics Committee of the Victorian 
Institute of Forensic Medicine and the Mental Health Research and 
Ethics Committee of Melbourne Health. The cohort used in this study 
was expanded from the cohort used in our microarray (Narayan 
et al., 2008). Due to limited tissue availability, the definition of SDS 
was expanded from <4 years as was used in our microarray study 
(Narayan et al., 2008) to <7 years duration of illness for this study 
to facilitate an increase in cohort size. Tissue from (BA46) of the left 
hemisphere was obtained post-mortem from 15 subjects diagnosed 
with schizophrenia <7 years prior to death and 15 subjects with no 
history of psychiatric illness (controls). For each subject, a   consensus 
introduCtion
Our recent microarray study of gene expression in the dorsola-
teral prefrontal cortex from subjects with schizophrenia of short 
(SDS) (<4 years) and long (LDS) (>22 years) duration of illness 
schizophrenia and age and sex matched controls reported altered 
expression of several low density lipoprotein receptor-related pro-
teins (LRP) associated with SDS (Narayan et al., 2008). LRP’s are a 
structurally diverse family of transmembrane receptors that share a 
common lipoprotein related receptor protein binding domain (May 
and Herz, 2003; May et al., 2005). In addition to lipid metabolism, 
they are involved in a diverse array of processes involved in neu-
ronal structural reorganization via interactions with glutamate, 
WNT signal transduction and APP processing (Beisiegel et al., 1989; 
Tamai et al., 2000; Hoe et al., 2006; Bell et al., 2007).
Whilst the LRP members serve as receptors for multiple of lig-
ands, it is significant that one of the major molecules that signal 
through the LRPs; Apolipoprotein E (APOE), has been implicated in 
the pathophysiology of schizophrenia (Harrington et al., 1995; Dean 
et al., 2003). Levels of ApoE protein expression have been reported 
to be increased in subjects with schizophrenia (Dean et al., 2003; 
Digney et al., 2005). By contrast, APOE expression is decreased in the 
periphery of subjects with schizophrenia (Dean et al., 2008) suggest-
ing an underlying level of complexity in the regulatory dysfunction 
of this protein. This is further evidenced by conflicting published 
data regarding the association between APOE polymorphisms and 
the incidence of schizophrenia (Harrington et al., 1995; Martinoli 
et al., 1995; Thibaut et al., 1998; Lee et al., 2001).Gibbons et al.  LRPs and APOE in schizophrenia
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To facilitate measurement of the target protein without the 
needing to measure reference proteins, the intra- and inter-assay 
variations for the measurement of APOE protein established for an 
internal standard according to well established protocols (Digney 
et al., 2005; Scarr et al., 2006a,b; Gibbons et al., 2008). Thirty micro-
grams of samples from an internal standard protein preparation 
derived from a subject independent of the cohort was loaded in 
repeat into 12 lanes per gel across two gels. The intra- and inter-
assay variation of the western data was <10% and <15% respectively. 
The internal standard is sample was subsequently run in duplicate 
on every gel, exposing each gel for a time that allowed the optical 
density of the internal standard to fall within the range established 
from the mean optical density of the assay variance gels ±2 standard 
deviations. Data from all subjects were standardized by expressing 
the antibody’s signal intensity of each subject as a ratio of the signal 
intensity of the membrane’s internal standard.
rna extraCtion and reverse transCription of the extraCt
Total RNA from was extracted from human post-mortem prefrontal 
cortex using a modification of the guanidine isothiocyanate–  phenol 
method  (Chomczynski  and  Sacchi,  1987)  using  Trizol  reagent 
(Invitrogen, Carlsbad, CA, USA) as described previously (Gibbons 
et al., 2009). The concentration, purity and integrity of the samples 
were determined using both spectrophotometry (Biospec Mini, 
Shimadzu Corporation, Kyoto, Japan) and a Bioanalyzer(Agilent 
Technologies, Santa Clara, CA, USA). Two micrograms of each RNA 
extract was reverse transcribed with 100 U MMLV (Ambion, Austin, 
TX, USA) in 500 mM Tris-HCl, pH 8.3, 750 mM KCl, 30 mM MgCl2 
50 mM DTT, 0.5 mM dNTP’s, 2.5 μM oligo dT primer, 2.5 μM ran-
dom decamers and 1 U/μl SUPERase In RNase inhibitor (Ambion, 
Austin, TX, USA). The reaction was incubated at 37°C for 1 h fol-
lowed by heat inactivation of the enzyme.
Quantitative real-tiMe pCr
qPCR of the sample cDNA was performed using the iQ5 real-time 
PCR detection system (Bio-Rad Laboratories, Hercules CA, USA). 
Oligonucleotides were designed using Beacon Designer 7.00 software 
(Premier Biosoft, Palo Alto, CA, USA) and the sequences are outlined 
in Table 3. The efficiencies of the oligonucleotides ranged between 
96.3% and 103.3%. qPCR reaction mixtures (50 μL) contained 
40 ng of reverse transcription product, 0.4 nM of complementary 
oligonucleotide pairs and 1X IQ SYBR green supermix (Bio-Rad 
Laboratories, Hercules, CA, USA). The PCR cycle parameters were 
95°C for 3 min and 40 cycles of 95°C for 10 s, 60°C for 15 s and 68°C 
for 15 s. qPCR data was acquired using IQ5 optical system 2.0 soft-
ware (Bio-Rad Laboratories, Hercules, CA, USA). All samples were 
run in triplicate and the expression of calculated from the log 2 of 
the average triplicate value corrected for primer efficiency. Expression 
was normalized against the geometric mean of GAPDH, PPIA and 
SNCA expression as previously described (Gibbons et al., 2009).
statistiCs
Grubbs test was used to identify outliers within the data and the 
data was subsequently analyzed by the D’Agostino and Pearson 
omnibus normality test to assess whether the data was normally 
distributed. Student’s t test was used to analyze the expression of 
the LRP genes. Statistical significance was accepted at P < 0.05. 
  diagnosis was reached between a   psychologist and a psychiatrist using 
the Diagnostic Instrument for Brain Studies (DIBS) (Keks et al., 1999); 
a semi-structured protocol for post-mortem assessment allowing psy-
chiatric diagnosis according to DSM-IV criteria (American Psychiatric 
Association, 1994). Cadavers were refrigerated within 5 h and brain 
tissue was frozen to −70°C within 30 min of autopsy. The period 
between death and autopsy was taken as the post-mortem interval 
(PMI) where death was witnessed. In cases where death was not wit-
nessed, only subjects who had been seen alive up to 5-h prior to being 
found dead were used in the study. In such instances, PMI was taken 
from the midpoint between the subject being found and being last 
seen alive. The pH of the CNS was measured as described previously 
(Kingsbury et al., 1995). Case details including demographic data and 
tissue quality markers are described in Table 1. Subject drug history 
and cause of death are described in Table 2.
Western Blotting
Homogenates were prepared from BA 46 tissue at 5% w/v in 10 mM 
Tris (pH 7.4), 1% SDS, 1 mM Na3VO4 and protein concentrations 
were determined using the Bio-Rad DC modified Lowry protein 
assay adapted for microplates. Thirty micrograms of protein sam-
ples were resolved on a 10% polyacrylamide gel. To minimize gel 
variation between diagnoses, protein samples from pair matched sub-
jects were loaded in duplicate in consecutive lanes on the same gel. 
Molecular weight standards were loaded onto each gel. The proteins 
were transferred on to nitrocellulose membranes. Equal loading and 
protein transfer were confirmed by staining with 0.2% ponceau S in 
3% trichloroacetic acid. The membranes were blocked in 5% non-fat 
milk powder in 1XTTBS, incubated in mouse anti-APOE monoclonal 
antibody (1:500, BD Biosciences, Franklin Lakes, NJ, USA; #610449) 
diluted in 5% milk powder in 1XTTBS for 1 h at RT. The membranes 
were then washed four times in 1XTTBS, incubated with HRP con-
jugated secondary antibody (1:1000, DAKO, Glostrup, Denmark; 
#P0447) and washed four times in 1XTTBS. The membranes were 
incubated with ECLTM (Amersham Biosciences, Amersham, UK) for 
1 min and then imaged and analyzed using the Kodak 440 CF imaging 
system (Kodak Scientific Imaging Systems, NewHaven, CT, USA).
Table 1 | A summary of the demographic and tissue condition data for 
subjects with short duration of illness schizophrenia (SDS) and control 
subjects used in the study. Gender data is described as the ratio of males 
(M) to females (F).
  Control  SDS
Gender  12 M: 3 F  12 M: 3 F
Age  29.9 ± 12.1 y  29.4 ± 12.5 y
Post-mortem interval  47 .3 ± 11.8 h  47 .5 ± 13.2 h
CNS pH  6.30 ± 0.21  6.29 ± 0.15
RIN  8.0 ± 1.0  7 .8 ± 1.4
Duration of illness    4.1 ± 1.8 y
Incidence of suicide  0/15  11/15
Antipsychotic medication    732.85 ± 780.74 mg
Incidence of suicide data is described as the number of subjects who committed 
suicide as a proportion of the sample size. All other data is listed as means ± the 
standard deviation. Antipsychotic mediation is listed as final prescribed dose of 
neuroleptic medication expressed as chlorpromazine equivalence per day. Gibbons et al.  LRPs and APOE in schizophrenia
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Table 2 | The cause of death and medication history of the subjects used in this study.
Control  Short Duration of Illness Schizophrenia (SDS)
Case Cause of death Case Cause of death Neuroleptics Anti-
depressants
Benzodiapines Anti-
cholinergics
Mood 
stabilizers
1 Trauma/
Asphyxia
16 Meningo-
encephalitis
Haloperidol 
Chlopromazine 
Clozapine 
Fluoxetine Benztropine
2 Coronary artery 
atheroma
17 CO poisoning Haloperidol Oxazepam 
Nitrazepam
3 Electrocution 18 CO poisoning Haloperidol  Desipramine  Clonazepam  Benztropine
4 Electrocution 19 Multiple injuries Haloperidol  Sertraline  (Diazapam) Benztropine
5 Acute epiglottitis 20 Unascertained Haloperidol 
Risperidone 
Chlorpromazine 
  Diazapam Benztropine
6 Dilated 
cardiomyopathy
21 Coronary artery 
thrombosis
Haloperidol Benztropine
7 Iatrogenic 
hemorrhage
22 Combined drug 
toxicity
Pimozide Sertraline 
(Moclobemide)
8 Ischemic heart 
disease
23 Hanging Haloperidol     Lithium
9 Exsanguination 24 Pericarditis Trifluoperazine 
Flupenthixol 
(Diazapam)
10 Exsanguination 25 Asphyxia plastic 
bag
Fluphenazine 
Chlorpromazine 
Temazapam Carbamazepine
11 Accidental 
drowning
26 Hanging Fluphenazine
12 Ventricular 
hypertrophy
27 Combined drug 
toxicity
Trifluoperazine Imipramine 
(Desipramine)
13 Myocarditis 28 CO poisoning Haloperidol Doxepin Benztropine 
14 Asthma attack 29 Hanging Haloperidol  Benztropine
15 Ischemic heart 
disease
30 CO poisoning Haloperidol Dosulepin Flunitrazepam Benztropine
Drugs that were detected following toxicological screening that were not recorded in the subject’s prescribed drug history are noted in brackets.
Table 3 | A summary of the oligonucleotide primers used for real-time PCR analysis of LRP expression. Commonly used synonyms are provided in 
brackets.
Gene  GenBank Accession #  Oligonucleotide sequence  Position 5′–3′ (bp)
LRP2 (Megalin)  NM_004525.2  F 5′-AGACTGGTTCTAACGCCTGTAATC-3′  3116–3139
    R 5′-GCTCTGTGGGTGGTTCATTGG-3′  3266–3286
LRP4 (MEG7)  NM_002334.2  F 5′-GAGTGAAAAGAGCCCAGTGC-3′  5138–5157
    R 5′-GGGGATTGGTTCAATCTTCA-3′  5473–5492
LRP6  NM_002336.2  F 5′-CTTGTCAGCAGAGGAGAACTATG -3′  4873–4895
    R 5′-CGTTGGAGGCAGTCAGAGG-3′  4999–5017
LRP8 (APOER2)  NM_004631.3  F 5′-CGGAACTATTCACGCCTCATC-3′  1460–1480
    R 5′-TGCTCTTTCGGGTCACTGG-3′  1587–1606
LRP10  NM_014045.3  F 5′-ATACACACCTAGCCTCAGTCTCC-3′  1176–1198
    R 5′-GCATCTCCAAAGCCCAAGTCC-3′  1270–1290
LRP12 (ST7)  NM_013437 .3  F 5′-GTGTGTTTGAAAGTTGGGTGTGTG-3′  1483–1506
    R 5′-CTATGACGGCAGCAGTGATGAC-3′  1572–1593Gibbons et al.  LRPs and APOE in schizophrenia
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normally used by our group. However, this analysis suggests that, 
with such cohorts, we would have detected a significant decrease 
in LRP2 mRNA in SDS.
potential Confounding faCtors
In our previous microarray study, the SDS group was defined as 
having a duration of illness of <4 years. In order to expand the 
size of the cohort in this study, the duration of illness of the SDS 
group was expanded to include subjects with a duration of illness 
<7 years. To determine whether expanding the definition of SDS 
impacted the data Pearson product moment correlation was used 
to assess the relationship between duration of illness and expres-
sion. There was no strong relationship between duration of illness 
(0.22 > R2 > 1.42 × 10−3; 0.90 > P > 0.13) and expression in any 
dataset. Tissue quality markers such as PMI, CNS pH and RIN can 
potentially reflect poor integrity of the protein and RNA. We found 
no significant difference in pH (t = 0.17; df = 28; P = 0.87), PMI 
(t = 0.44; df = 28; P = 0.67) or RIN (t = 0.54; df = 28; P = 0.60) 
between diagnostic groups the integrity of our tissue is not likely to 
impact our data. Demographic factors that could potentially reflect 
environmental heterogeneity of the samples were also examined. 
There was no significant difference in gender (df = 1; P = 1.00) 
or age (U = 104.50; P = 0.75) between diagnostic groups. The 
incidence of suicide was increased in subjects with schizophrenia 
(df = 1; P < 0.01) compared to controls, however, there was no 
strong correlation between the incidence of suicide and the expres-
sion levels suggesting the incidence of suicide was unlikely to impact 
our data (df = 12; 0.18 > R2 > 1.29 × 10−4; 0.97 > P > 0.35).
As antipsychotic drug use has been associated with altered lipid 
metabolism (Bustillo et al., 1996; de Leon et al., 2007). Therefore, 
it was necessary to determine whether the past drug history of 
our subjects impacted our data. While all subjects in the schizo-
phrenia group had been prescribed antipsychotic medication, two 
subjects had also been prescribed atypical antipsychotic medica-
tion (clozapine and risperidone). Data from these subjects did not 
represent unusually high or low values compared to the rest of the 
The relationship between demographic and tissue condition data 
were assessed using Pearson product moment correlation. R2 > 0.7 
was considered to be a strong relationship (Gliner et al., 2002). 
Analyses were conducted using Prism 5.01 (Graphpad Software, 
La Jolla, CA, USA) and Minitab 13.01 (Minitab, State College, PA, 
USA) software.
results
qPCR was not completed on one case (Case #28) because of a RIN 
of 3.5 which is indicative of poorly preserved mRNA. Examining 
each data set for outliers, the expression of LRP6 in Case #8, LRP8 
in Case #29 and LRP 10 in Case #14 were identified as significant 
outliers (Z = 2.54; P < 0.05). These data points were, therefore, 
excluded from further analysis.
All data sets except the LRP6 (K2 = 9.19; P = 0.01) measurements 
in controls followed a Gaussian distribution (5.009 < K2 < 0.08; 
0.96 < P < 0.08). Therefore, LRP6 data was analyzed using non-
parametric statistics while all other data was analyzed using para-
metric statistics. As we could not assume a relationship between 
the   expression of the genes examined, Student’s t test or Mann–
Whitney’s U test was used to analyze the expression of the LRP genes. 
Statistical significance was accepted at P < 0.05. Confirming this 
assumption, multiple Pearson product moment correlation analysis 
failed to show a strong relationship between the expression levels 
of the individual genes against the other genes examined (LRP2: 
df = 5; R2 < 0.01; 0.60 > P > 0.55; LRP4: df = 5; 0.09 > R2 > 0.01; 
0.71 > P > 0.38; LRP6: df = 5; 0.13 > R2 > 0.01; 0.69 > P > 0.34; LRP8: 
df = 5; 0.14 > R2 > 0.11; 0.37 > P > 0.33; LRP10: df = 5; 0.57 > R2 > 0.46; 
0.08 > P > 0.05; LRP12: df = 5; 0.27 > R2 > 0.08; 0.47 > P > 0.22).
Western Blot analysis
APOE protein expression was measured using western blotting. The 
predicted immunogenic band at 36 kDa was detected by the anti-
APOE antibody in each sample (Figure 1A). Levels of APOE were 
significantly increased in subjects with SDS compared to controls 
(U = 51.00; P = 0.01) (Figure 1B).
qpCr analysis
Although measuring LRP protein levels, as the functional gene 
product, would have been ideal, we were unable to obtain reli-
able antibodies against the LRPs to measure protein expression. 
Therefore,  we  measured  LRP  mRNA  expression  instead  using 
qPCR. Only LRP’s that were highlighted as potentially altered 
in initial microarray screen were examined. LRP10 mRNA levels 
were increased in subjects with SDS compared to controls (t = 1.91; 
df = 26; P = 0.03) (Figure 2A). Conversely, there was a decrease 
in LRP12 mRNA levels in subjects with SDS compared to con-
trols (t = 3.17; df = 27; P < 0.01) (Figure 2B). Levels of mRNA 
for all other LRPs did not vary significantly with diagnosis: LRP2 
(t = 1.42; df = 27; P = 0.08) (Figure 2C), LRP4 (t = 0.78; df = 27; 
P = 0.22) (Figure 2D), LRP6 (U = 81.00; P = 0.22) (Figure 2E) 
and LRP8 (t = 0.19; df = 26; P = 0.42) (Figure 2F). As there was 
a trend towards a significant decrease in LRP2 mRNA in SDS we 
completed a power analysis of these data which showed that the 
data would become significant with cohort sizes of n = 19. Due 
to a limited availability of tissue from subjects with SDS, we were 
unable to expand the size of this cohort to the n = 20 cohort sizes 
FIGuRE 1 | Western analysis of APOE protein expression in subjects with 
short duration of illness schizophrenia (SDS) was performed on a 36-kDa 
immunogenic band, which corresponded to the predicted size of APOE 
(A). The level of APOE protein expression was increased Brodmann’s area 46 
from subjects with SDS compared to controls (B). Values are expressed as 
ratios of APOE expression in an independent BA9 protein extract (internal 
standard) * P < 0.05.Gibbons et al.  LRPs and APOE in schizophrenia
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study, we did not detect altered levels of APOE mRNA expression in 
SDS a subset (n = 8) of subjects used in this study (Narayan et al., 
2008). Thus, the greater number of subjects used in this study may 
increase our power to detect a change in expression, or the increase 
in APOE protein measured in this study may be caused by changes 
in either post-transcriptional regulation of expression or the rate 
of degradation of the APOE protein.
Our study is novel in that we have also studied a family of 
receptors, some of which are used by APOE for signaling. These 
investigations have shown that mRNA for LRP10 is increased and 
mRNA for LRP12 is decreased in SDS, which is in agreement with 
our microarray data (Narayan et al., 2008). There is also a trend 
towards decrease in LRP2 mRNA in SDS which again reproduces 
findings on the gene using microarrays (Narayan et al., 2008).
At present little is known about the role of some LRPs in the 
CNS, however, it is possible be that the decrease in LRP10 expres-
sion is a normal physiological response to increased levels of APOE 
in the CNS of individuals with SDS. However, the fact that we have 
cohort and removing these subjects from analysis did no alter the 
level of significant difference in any dataset. There was no strong 
  relationship between antipsychotic drug use expression in any other 
dataset (0.47 > R2 > 8.21 × 10−3; 0.76 > P > 0.01).
When the distribution of the expression data was visually exam-
ined, there appeared to be discrete clusters of data points within 
the control data sets for APOE (Figure 1), LRP2 (Figure 2C) and 
LRP4 (Figure 2D) that were separated from the main population 
of subjects. Neither the confounding factors examined nor the 
experimental bias could account for these clusters. Therefore, the 
observed distribution is likely to reflect the normal heterogeneity 
of expression levels for these genes.
disCussion
Our finding of increased APOE protein expression in BA46 in 
subjects with SDS adds to previous findings of increased APOE 
protein expression associated with schizophrenia in BA46 and BA9 
(Dean et al., 2003; Digney et al., 2005). In our previous microarray 
FIGuRE 2 | Levels of (A) LRP10, (B) LRP12, (C) LRP2, (D) LRP4, (E) LRP6 and (F) LRP8 mRNA expression in Brodmann’s area 46 from subjects with short 
duration of illness schizophrenia (SDS) and controls. LRP expression data is expressed as a ratio of the geometric mean of PPIA, SNCA and GAPDH expression. 
* P < 0.05; ** P < 0.01.Gibbons et al.  LRPs and APOE in schizophrenia
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gene expression than haloperidol. This raises the possibility that 
abnormalities in lipid metabolism may be present in the CNS of 
subjects with schizophrenia early in the progression of the disorder 
and that these changes may be made worse by atypical antipsychotic 
drug treatment. The observation in our previous microarray study 
that altered LRP expression is associated with the period following 
diagnosis and is not maintained throughout the progression of 
the disorder would support the notion that altered LRP expres-
sion reflects a predisposition to metabolic dysfunction (Narayan 
et al., 2009). By contrast, an exacerbation of altered LRP expres-
sion in response to antipsychotic medication might be expected 
in response to the prolonged drug treatment in LDS. Given the 
well established link between peripheral metabolic problems and 
treatment with some antipsychotic drugs (Mackin et al., 2005), this 
phenomenon would warrant further investigation.
We were unable to ascertain the racial background or APOE 
genotypes of the subjects used in this study. Evidence surround-
ing the role of the major APOE polymorphisms in the pathology 
of schizophrenia is inconclusive (Harrington et al., 1995; Chen 
et al., 1999; Durany et al., 2000). Furthermore, we have previously 
reported that increased APOE expression in BA9 is not associated 
with APOE genotype (Dean et al., 2003), suggesting our data is 
unlikely to be impacted by the genotypes of our subjects. Our study 
was also limited by the inability to obtain substance abuse histories 
of for our subjects and we cannot exclude the influence of drug 
abuse on our data set.
Our study adds to other studies that have implicated altered 
lipid metabolism and apolipoprotein signaling in the pathology of 
schizophrenia (Thomas et al., 2001; Dean et al., 2003). Moreover, 
we have demonstrated these changes in lipid metabolism within 
the dorsolateral prefrontal cortex, which has well established roles 
in cognition (Levy and Goldman-Rakic, 1999; Perlstein et al., 2001; 
Yoon et al., 2008). Procedural cognitive deficits in schizophrenia 
have been shown to predict the capacity for non-verbal social func-
tioning (Kawakubo et al., 2006). It is, therefore, significant that 
analogous procedural cognitive deficits are displayed by APOE−/− 
mice (Champagne et al., 2002). Furthermore, dietary challenged 
APOE−/− mice show deficits in spatial learning deficits (Troen et al., 
2006). These latter data, alongside our findings, may indicate that 
changes in lipid metabolism in the dorsolateral prefrontal cortex 
of subjects with SDS could be associated with the genesis of the 
cognitive deficits displayed by most subjects with schizophrenia 
(Berman and Weinberger, 1990).
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shown altered levels of expression of LRP10 and LRP12 expression 
in the dorsolateral cortex of subjects with schizophrenia would 
add weight to the argument that lipoprotein signaling is altered in 
SDS. The ligands that activate LRP10 and LRP12 have not yet been 
fully characterized. It is known that APOE-enriched VLDL signals 
through LRP10 (Sugiyama et al., 2000) again adding support for 
APOE signaling being disrupted in SDS. Moreover, there are strong 
structural homologies between LRP10 and LRP12 (Sugiyama et al., 
2000), suggesting that both proteins will act as APOE receptors and, 
therefore, it would not be unreasonable to suggest that the changes 
we observed in LRP12 are a further indication of abnormal APOE 
signaling in the CNS of subjects with schizophrenia. It is, however, 
notable that LRP8, which is well established as a major receptor for 
APOE, was not altered in SDS. Similarly, there was no evidence from 
our original microarray study that another major APOE receptor, 
LRP1, was altered in SDS (Narayan et al., 2008). Both LRP1 and LRP8 
bind to a number of other ligands in addition to APOE (May et al., 
2005). Therefore, the expression of these LRPs may be less likely to 
be affected by altered expression of a single ligand, such as APOE.
We did not find changes in LRP4, LRP6 and LRP8 mRNA expres-
sion associated with SDS. This contrasts the finding of decreased 
LRP4 mRNA levels from our microarray study (Narayan et al., 
2008). These differences may have resulted from an increase in 
heterogeneity in our cohort that was introduced when expanding 
the sample size of the original SDS cohort. However, we found no 
association between duration of illness and expression levels to sug-
gest that this was the case. It has been recognized that there may be 
poor correlation between microarray and qPCR data, particularly 
where the changes gene expression are small in magnitude (Morey 
et al., 2006). Real-time PCR analysis is a more sensitive method for 
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